Form 4: Oncotelic Therapeutics CEO Trieu Vuong Acquires 500,000 Shares
SEC Form 4
Oncotelic Therapeutics' CEO, Trieu Vuong, purchased 500,000 shares of the company's common stock at $0.02 per share on August 23, 2024.
Summary
- On August 23, 2024, Trieu Vuong, the Chairman and CEO of Oncotelic Therapeutics, Inc., acquired 500,000 shares of common stock.
- The shares were purchased on the open market at a price of $0.02 per share.
- Following the transaction, Vuong directly owns 92,544,217 shares.
- Vuong also indirectly owns 16,780,384 shares through Autotelic, Inc. and 6,872,529 shares through his spouse.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CEO's purchase of shares is generally a good sign, but the low price per share ($0.02) and the company's history should be considered.
Positives
- The CEO's purchase of shares could be interpreted as a positive signal about the company's prospects.
Industry Context
Insider buying is often seen as a positive sign, suggesting that a company's leadership believes the stock is undervalued. However, it's important to consider the size of the purchase relative to the executive's overall holdings and the company's market capitalization.
Key Dates
| Date | Description |
|---|---|
| 08/23/2024 | CEO Trieu Vuong purchased 500,000 shares of Oncotelic Therapeutics at $0.02 per share. |
| 08/27/2024 | Date of signature for the SEC Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.